Benzolamide

Benzolamide (CL11366) is a potent carbonic anhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures[1][2][3].

Product Specifications

CAS Number

[3368-13-6]

Product Name Alternative

CL11366

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Carbonic Anhydrase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/benzolamide.html

Concentration

10mM

Purity

99.59

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=S(C1=NN=C(S1)NS(=O)(C2=CC=CC=C2)=O)(N)=O

Molecular Formula

C8H8N4O4S3

Molecular Weight

320.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Prete SD, et, al. Escherichia coli γ-carbonic anhydrase: characterisation and effects of simple aromatic/heterocyclic sulphonamide inhibitors. J Enzyme Inhib Med Chem. 2020 Dec;35 (1) :1545-1554.|[2]Vullo D, et, al. Sulfonamide Inhibition Studies of the β-Class Carbonic Anhydrase CAS3 from the Filamentous Ascomycete Sordaria macrospora. Molecules. 2020 Feb 25;25 (5) :1036.|[3]Pospelov AS, et, al. Carbonic anhydrase inhibitors suppress seizures in a rat model of birth asphyxia. Epilepsia. 2021 Jun 27.